Home  Media Press releases 1999
|
|
|
| 17 November 1999 | 1999-11-17T00:00:00.0000000-00:00 |
|
ASTRAZENECA ENTITLED TO INTERLOCUTORY* INJUNCTION TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE IN ISRAEL
AstraZeneca today announced that the Tel Aviv District Court has held that AstraZeneca is entitled to an interlocutory injunction in Israel based on the formulation patent, to prevent Dexcel Ltd. from marketing a generic omeprazole product.
|
Omeprazole is the substance used in Losec®. The interlocutory injunction will not come into effect until the Supreme Court in Israel has considered Dexcel's application for leave to appeal.
| |
-
The substance patent for omeprazole began expiry in the first countries in 1999. In most countries AstraZeneca has been granted Patent Term Extensions or Supplementary Protection Certificates (SPCs). This extended coverage expires in the US in April 2001, in most European countries in 2002 - 2004, and in Japan in 2004. The product is also protected by patents directed to formulation, uses, intermediates and processes.
|
|
|
|